InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.023 -0.028 (-54.90%)+
Announcement
Release
13 Jul 2026 9:38AM
Price at Release
$0.051
Full Release
download
Summary
Immutep Limited announced significant advancements in their clinical trials for 1st line non-small cell lung cancer (NSCLC), presenting positive mature overall survival data from the INSIGHT-003 study, with a median overall survival (mOS) of 30.9 months. This study notably includes a high percentage of patients with low PD-L1 expression. The TACTI-004 Phase III trial was discontinued following a futility analysis, as the objective response rate in the treatment group was inferior to the control. Preliminary immune monitoring indicates a distinct activation profile in the TACTI-004 study compared to previous studies. Eftilagimod alfa (efti), Immutep's novel immunotherapy, continues to show promise in enhancing anti-tumor immune responses, particularly in populations with unmet medical needs. Further analysis and updates on these trials are expected later in the year.
Key Points
  • Immutep Limited provides a clinical update for 1st line NSCLC.
  • INSIGHT-003 shows mature median Overall Survival (mOS) of 30.9 months in 1L NSCLC.
  • Approximately 92% of INSIGHT-003 patients had no or low PD-L1 expression.
  • TACTI-004 Phase III trial was discontinued due to futility.
  • TACTI-004 showed a lower objective response rate than the control arm.
  • Preliminary data from TACTI-004 shows different immune activation profiles.
  • Ongoing analysis for TACTI-004 with results expected in Q3 CY2026.
  • Eftilagimod alfa (efti) engages both adaptive and innate immune responses.
  • Immutep is developing immunotherapies based on Lymphocyte Activation Gene-3 (LAG-3).
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.